Ignite Creation Date:
2024-05-06 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05237388
Status:
RECRUITING
Last Update Posted:
2024-03-21
First Post:
2022-01-31
Brief Title:
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
Sponsor:
Duke University
Organization:
Duke University
Study Overview
Official Title:
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
JUSTICE
Brief Summary:
The purpose of this study is to determine if the drug baricitinib is safe and effective in reducing high levels of albumin in the urine albuminuria in African AmericanBlacks with APOL1- associated focal segmental glomerulosclerosis FSGS and non-diabetic APOL1-associated chronic kidney disease due to hypertension HTN-CKD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01MD016401-01 | NIH | None | httpsreporternihgovquickSearchR01MD016401-01 |